PMID- 21511216
OWN - NLM
STAT- MEDLINE
DCOM- 20110815
LR  - 20181201
IS  - 1876-7605 (Electronic)
IS  - 1936-8798 (Linking)
VI  - 4
IP  - 4
DP  - 2011 Apr
TI  - Clopidogrel and proton pump inhibitors: influence of pharmacological interactions 
      on clinical outcomes and mechanistic explanations.
PG  - 365-80
LID - 10.1016/j.jcin.2010.12.009 [doi]
AB  - Dual antiplatelet therapy with aspirin and clopidogrel is associated with a 
      significant reduction in vascular ischemic events; however, gastrointestinal 
      bleeding events are a major concern in high-risk and older patients. Clinical 
      practice guidelines recommend combination therapy with proton pump inhibitors 
      (PPI) and dual antiplatelet therapy to attenuate gastrointestinal bleeding risk. 
      In addition, high on-treatment platelet reactivity has been associated with 
      recurrent ischemic events. Whether or not the pharmacological interaction between 
      clopidogrel and PPI, which results in diminished antiplatelet effect, adversely 
      influences clinical efficacy is highly controversial and the subject of debate. 
      Based on largely anecdotal post-hoc analyses, the U.S. Federal Drug 
      Administration's and European Medicines Agency's recommendations discourage PPI 
      use (particularly omeprazole) in patients treated with clopidogrel. However, many 
      American College of Cardiology/American Heart Association/Society for 
      Cardiovascular Angiography and Interventions experts do not support change in 
      clinical practice guidelines recommendations without adequately powered, 
      prospective, randomized clinical trial data.
CI  - Copyright (c) 2011 American College of Cardiology Foundation. Published by Elsevier 
      Inc. All rights reserved.
FAU - Tantry, Udaya S
AU  - Tantry US
AD  - Sinai Center for Thrombosis Research, Sinai Hospital of Baltimore, Baltimore, 
      Maryland 21215, USA.
FAU - Kereiakes, Dean J
AU  - Kereiakes DJ
FAU - Gurbel, Paul A
AU  - Gurbel PA
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - JACC Cardiovasc Interv
JT  - JACC. Cardiovascular interventions
JID - 101467004
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 0 (Proton Pump Inhibitors)
RN  - A74586SNO7 (Clopidogrel)
RN  - OM90ZUW7M1 (Ticlopidine)
SB  - IM
MH  - Animals
MH  - Biotransformation/genetics
MH  - Cardiovascular Diseases/blood/*prevention & control
MH  - Clopidogrel
MH  - Drug Interactions
MH  - Evidence-Based Medicine
MH  - Gastrointestinal Hemorrhage/chemically induced/*prevention & control
MH  - Humans
MH  - Platelet Aggregation/*drug effects
MH  - Platelet Aggregation Inhibitors/adverse effects/pharmacokinetics/*therapeutic use
MH  - Polymorphism, Genetic
MH  - Practice Guidelines as Topic
MH  - Proton Pump Inhibitors/adverse effects/pharmacokinetics/*therapeutic use
MH  - Risk Assessment
MH  - Risk Factors
MH  - Ticlopidine/adverse effects/*analogs & derivatives/pharmacokinetics/therapeutic 
      use
EDAT- 2011/04/23 06:00
MHDA- 2011/08/16 06:00
CRDT- 2011/04/23 06:00
PHST- 2010/11/19 00:00 [received]
PHST- 2010/12/14 00:00 [revised]
PHST- 2010/12/26 00:00 [accepted]
PHST- 2011/04/23 06:00 [entrez]
PHST- 2011/04/23 06:00 [pubmed]
PHST- 2011/08/16 06:00 [medline]
AID - S1936-8798(11)00086-0 [pii]
AID - 10.1016/j.jcin.2010.12.009 [doi]
PST - ppublish
SO  - JACC Cardiovasc Interv. 2011 Apr;4(4):365-80. doi: 10.1016/j.jcin.2010.12.009.